The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.
Relative Mitochondrial Priming of Myeloblasts and Normal HSCs Determines Chemotherapeutic Success in AML
Open accessAbstract
Summary Despite decades of successful use of cytotoxic chemotherapy in acute myelogenous leukemia (AML), the biological basis for its differential success among individuals and for the existence of a therapeutic index has remained obscure. Rather than taking a genetic approach favored by many, we took a functional approach to ask how differential mitochondrial readiness for apoptosis (“priming”) might explain individual variation in clinical behavior. We found that mitochondrial priming measured by BH3 profiling was a determinant of initial response to induction chemotherapy, relapse following remission, and requirement for allogeneic bone marrow transplantation. Differential priming between malignant myeloblasts and normal hematopoietic stem cells supports a mitochondrial basis to the therapeutic index for chemotherapy. BH3 profiling identified BCL-2 inhibition as a targeted strategy likely to have a useful therapeutic index. BH3 profiling refines predictive information provided by conventional biomarkers currently in use, and thus may itself have utility as a clinical predictive biomarker.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A cell initiating human acute myeloid leukaemia after transplantation into SCID mice
Lapidot, T., Sirard, C., Vormoor, J., Murdoch, B., Hoang, T., Caceres-Cortes, J., Minden, M., Paterson, B., Caligiuri, M. A., & Dick, J. E. (1994) · Nature · doi:10.1038/367645a0 · Cited by 4,783
The Release of Cytochrome c from Mitochondria: A Primary Site for Bcl-2 Regulation of Apoptosis
Kluck, R. M., Bossy-Wetzel, E., Green, D. R., & Newmeyer, D. D. (1997) · Science · doi:10.1126/science.275.5303.1132 · Cited by 4,714
Danial, N. N., & Korsmeyer, S. J. (2004) · Cell · doi:10.1016/s0092-8674(04)00046-7 · Cited by 4,651
Proapoptotic BAX and BAK: A Requisite Gateway to Mitochondrial Dysfunction and Death
Wei, M. C., Zong, W.-X., Cheng, E. H.-Y., Lindsten, T., Panoutsakopoulou, V., Ross, A. J., Roth, K. A., MacGregor, G. R., Thompson, C. B., & Korsmeyer, S. J. (2001) · Science · doi:10.1126/science.1059108 · Cited by 3,988
An inhibitor of Bcl-2 family proteins induces regression of solid tumours
Oltersdorf, T., Elmore, S. W., Shoemaker, A. R., Armstrong, R. C., Augeri, D. J., Belli, B. A., Bruncko, M., Deckwerth, T. L., Dinges, J., Hajduk, P. J., et al. (2005) · Nature · doi:10.1038/nature03579 · Cited by 3,416
Self-citationDöhner, H., Estey, E. H., Amadori, S., Appelbaum, F. R., Büchner, T., Burnett, A. K., Dombret, H., Fenaux, P., Grimwade, D., Larson, R. A., et al. (2010) · Blood · doi:10.1182/blood-2009-07-235358 · Cited by 3,373
An APAF-1·Cytochrome c Multimeric Complex Is a Functional Apoptosome That Activates Procaspase-9
Zou, H., Li, Y., Liu, X., & Wang, X. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.17.11549 · Cited by 2,090
ABT-263: A Potent and Orally Bioavailable Bcl-2 Family Inhibitor
Tse, C., Shoemaker, A. R., Adickes, J., Anderson, M. G., Chen, J., Jin, S., Johnson, E. F., Marsh, K. C., Mitten, M. J., Nimmer, P., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-5836 · Cited by 1,992
Chen, L., Willis, S. N., Wei, A., Smith, B. J., Fletcher, J. I., Hinds, M. G., Colman, P. M., Day, C. L., Adams, J. M., & Huang, D. C. S. (2005) · Molecular Cell · doi:10.1016/j.molcel.2004.12.030 · Cited by 1,816
Targeting DNA topoisomerase II in cancer chemotherapy
Nitiss, J. L. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2607 · Cited by 1,791
Cited by
Control of apoptosis by the BCL-2 protein family: implications for physiology and therapy
Czabotar, P. E., Lessene, G., Strasser, A., & Adams, J. M. (2014) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3722 · Cited by 3,219
Targeting apoptosis in cancer therapy
Carneiro, B. A., & El-Deiry, W. S. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-0341-y · Cited by 2,542
Regulation of apoptosis in health and disease: the balancing act of BCL-2 family proteins
Singh, R., Letai, A., & Sarosiek, K. (2019) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-018-0089-8 · Cited by 2,111
Self-citationDiNardo, C. D., Pratz, K., Pullarkat, V., Jonas, B. A., Arellano, M., Becker, P. S., Frankfurt, O., Konopleva, M., Wei, A. H., Kantarjian, H. M., et al. (2019) · Blood · doi:10.1182/blood-2018-08-868752 · Cited by 1,825
Self-citationZhu, Y., Tchkonia, T., Fuhrmann‐Stroissnigg, H., Dai, H. M., Ling, Y. Y., Stout, M. B., Pirtskhalava, T., Giorgadze, N., Johnson, K. O., Giles, C. B., et al. (2016) · Aging Cell · doi:10.1111/acel.12445 · Cited by 1,148
Konopleva, M., Pollyea, D. A., Potluri, J., Chyla, B., Hogdal, L., Busman, T., McKeegan, E., Salem, A. H., Zhu, M., Ricker, J. L., et al. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-0313 · Cited by 1,064
Self-citationDrugging Topoisomerases: Lessons and Challenges
Pommier, Y. (2013) · ACS Chemical Biology · doi:10.1021/cb300648v · Cited by 839
Mitochondrial apoptosis: killing cancer using the enemy within
Lopez, J., & Tait, S. W. G. (2015) · British Journal of Cancer · doi:10.1038/bjc.2015.85 · Cited by 784
Thirty years of BCL-2: translating cell death discoveries into novel cancer therapies
Delbridge, A. R. D., Grabow, S., Strasser, A., & Vaux, D. L. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2015.17 · Cited by 752
Selective BCL-2 Inhibition by ABT-199 Causes On-Target Cell Death in Acute Myeloid Leukemia
Pan, R., Hogdal, L. J., Benito, J. M., Bucci, D., Han, L., Borthakur, G., Cortes, J., DeAngelo, D. J., Debose, L., Mu, H., et al. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0609 · Cited by 735
Self-citationDrugging the p53 pathway: understanding the route to clinical efficacy
Khoo, K. H., Verma, C. S., & Lane, D. P. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4236 · Cited by 719
To Be or Not to Be? How Selective Autophagy and Cell Death Govern Cell Fate
Green, D. R., & Levine, B. (2014) · Cell · doi:10.1016/j.cell.2014.02.049 · Cited by 693
BCL-2 proteins and apoptosis: Recent insights and unknowns
Edlich, F. (2018) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2017.06.190 · Cited by 632
The BCL2 Family: Key Mediators of the Apoptotic Response to Targeted Anticancer Therapeutics
Hata, A. N., Engelman, J. A., & Faber, A. C. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-0011 · Cited by 619
Fernald, K., & Kurokawa, M. (2013) · Trends in Cell Biology · doi:10.1016/j.tcb.2013.07.006 · Cited by 579
Isocitrate dehydrogenase 1 and 2 mutations induce BCL-2 dependence in acute myeloid leukemia
Chan, S. M., Thomas, D., Corces-Zimmerman, M. R., Xavy, S., Rastogi, S., Hong, W.-J., Zhao, F., Medeiros, B. C., Tyvoll, D. A., & Majeti, R. (2015) · Nature Medicine · doi:10.1038/nm.3788 · Cited by 577
Precision medicine for cancer with next-generation functional diagnostics
Friedman, A. A., Letai, A., Fisher, D. E., & Flaherty, K. T. (2015) · Nature Reviews Cancer · doi:10.1038/nrc4015 · Cited by 570
Self-citationThe BCL-2 arbiters of apoptosis and their growing role as cancer targets
Adams, J. M., & Cory, S. (2018) · Cell Death & Differentiation · doi:10.1038/cdd.2017.161 · Cited by 530
DiNardo, C. D., Rausch, C. R., Benton, C., Kadia, T., Jain, N., Pemmaraju, N., Daver, N., Covert, W., Marx, K. R., Mace, M., et al. (2018) · American Journal of Hematology · doi:10.1002/ajh.25000 · Cited by 424
Drug-Induced Death Signaling Strategy Rapidly Predicts Cancer Response to Chemotherapy
Montero, J., Sarosiek, K. A., DeAngelo, J. D., Maertens, O., Ryan, J., Ercan, D., Piao, H., Horowitz, N. S., Berkowitz, R. S., Matulonis, U., et al. (2015) · Cell · doi:10.1016/j.cell.2015.01.042 · Cited by 378
Self-citationModes of Regulated Cell Death in Cancer
Koren, E., & Fuchs, Y. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-0789 · Cited by 371
Functional precision cancer medicine—moving beyond pure genomics
Letai, A. (2017) · Nature Medicine · doi:10.1038/nm.4389 · Cited by 366
Self-citationMitochondria—Judges and Executioners of Cell Death Sentences
Bhola, P. D., & Letai, A. (2016) · Molecular Cell · doi:10.1016/j.molcel.2016.02.019 · Cited by 326
Self-citationWhy do BCL-2 inhibitors work and where should we use them in the clinic?
Montero, J., & Letai, A. (2018) · Cell Death & Differentiation · doi:10.1038/cdd.2017.183 · Cited by 327
Self-citationPathways and mechanisms of venetoclax resistance
Bose, P., Gandhi, V., & Konopleva, M. (2017) · Leukemia & Lymphoma · doi:10.1080/10428194.2017.1283032 · Cited by 302
Pullarkat, V. A., Lacayo, N. J., Jabbour, E., Rubnitz, J. E., Bajel, A., Laetsch, T. W., Leonard, J., Colace, S. I., Khaw, S. L., Fleming, S. A., et al. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-1465 · Cited by 302
Towards precision medicine for AML
Döhner, H., Wei, A. H., & Löwenberg, B. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00509-w · Cited by 301
Treatment of Relapsed Acute Myeloid Leukemia
Thol, F., & Ganser, A. (2020) · Current Treatment Options in Oncology · doi:10.1007/s11864-020-00765-5 · Cited by 288
BH3-Mimetic Drugs: Blazing the Trail for New Cancer Medicines
Merino, D., Kelly, G. L., Lessene, G., Wei, A. H., Roberts, A. W., & Strasser, A. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.11.004 · Cited by 287
Letai, A., Bhola, P., & Welm, A. L. (2022) · Cancer Cell · doi:10.1016/j.ccell.2021.12.004 · Cited by 281
Self-citationChonghaile, T. N., Roderick, J. E., Glenfield, C., Ryan, J., Sallan, S. E., Silverman, L. B., Loh, M. L., Hunger, S. P., Wood, B., DeAngelo, D. J., et al. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-14-0353 · Cited by 275
Self-citationTargeted apoptosis of myofibroblasts with the BH3 mimetic ABT-263 reverses established fibrosis
Lagares, D., Santos, A., Grasberger, P. E., Liu, F., Probst, C. K., Rahimi, R. A., Sakai, N., Kuehl, T., Ryan, J., Bhola, P., et al. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aal3765 · Cited by 246
Self-citationDifferential retrotranslocation of mitochondrial Bax and Bak
Todt, F., Cakir, Z., Reichenbach, F., Emschermann, F., Lauterwasser, J., Kaiser, A., Ichim, G., Tait, S. W., Frank, S., Langer, H. F., et al. (2015) · The EMBO Journal · doi:10.15252/embj.201488806 · Cited by 172
Moncsek, A., Al‐Suraih, M. S., Trussoni, C. E., O'Hara, S. P., Splinter, P. L., Zuber, C., Patsenker, E., Valli, P. V., Fingas, C. D., Weber, A., et al. (2018) · Hepatology · doi:10.1002/hep.29464 · Cited by 136
Current status and new treatment approaches in TP53 mutated AML
Hunter, A. M., & Sallman, D. A. (2019) · Best Practice & Research Clinical Haematology · doi:10.1016/j.beha.2019.05.004 · Cited by 102
A matter of life and death: stem cell survival in tissue regeneration and tumour formation
Soteriou, D., & Fuchs, Y. (2018) · Nature Reviews Cancer · doi:10.1038/nrc.2017.122 · Cited by 87
A BH3 Mimetic for Killing Cancer Cells
Green, D. R. (2016) · Cell · doi:10.1016/j.cell.2016.05.080 · Cited by 79
Mitochondria: The metabolic switch of cellular oncogenic transformation
Tan, Y. Q., Zhang, X., Zhang, S., Zhu, T., Garg, M., Lobie, P. E., & Pandey, V. (2021) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2021.188534 · Cited by 75
Aberrant splicing and drug resistance in AML
de Necochea-Campion, R., Shouse, G. P., Zhou, Q., Mirshahidi, S., & Chen, C.-S. (2016) · Journal of Hematology & Oncology · doi:10.1186/s13045-016-0315-9 · Cited by 66
BCL-XL expression is essential for human erythropoiesis and engraftment of hematopoietic stem cells
Afreen, S., Bohler, S., Müller, A., Demmerath, E.-M., Weiss, J. M., Jutzi, J. S., Schachtrup, K., Kunze, M., & Erlacher, M. (2020) · Cell Death & Disease · doi:10.1038/s41419-019-2203-z · Cited by 55
Gutierrez-Martinez, P., Hogdal, L., Nagai, M., Kruta, M., Singh, R., Sarosiek, K., Nussenzweig, A., Beerman, I., Letai, A., & Rossi, D. J. (2018) · Nature Cell Biology · doi:10.1038/s41556-018-0054-y · Cited by 60
Self-citationLoss of dE2F compromises mitochondrial function
Ambrus, A. M., Islam, A. B. M. M. K., Holmes, K. B., Moon, N. S., Lopez-Bigas, N., Benevolenskaya, E. V., & Frolov, M. V. (2013) · Developmental Cell · doi:10.1016/j.devcel.2013.10.002 · Cited by 34
Short-term senolytic treatment: a paradigm to promote fracture repair during aging
Beerman, I., Basisty, N., & de Cabo, R. (2022) · Journal of Clinical Investigation · doi:10.1172/jci158871 · Cited by 15
Metadata
- Authors
- Vo, T.-T., Ryan, J., Carrasco, R., Neuberg, D., Rossi, D. J., Stone, R. M., DeAngelo, D. J., Frattini, M. G., & Letai, A.
- Venue
- Cell
- Publisher
- Elsevier BV
- Published
- 2012-10
- Volume
- 151
- Issue
- 2
- Pages
- 344-355
- ISSN
- 0092-8674 (ISSN-L)
- OpenAlex
- W2083086786
- Cited by
- 348
- References
- 37
- FWCI
- 16.33
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.